15/06/2026
Ease your patients' discomfort with Flamigel® RT. Clinically proven to alleviate radiotherapy-induced skin reactions, it offers reliable relief. Recommend Flamigel® RT to empower your patients in managing their pain during treatment.
1.Johnson K, Fenton G, and White RJ. (2021) Radiation dermatitis: the evaluation of a new topical therapy for the treatment and prevention of radiation-induced skin damage and moist desquamation: a multicentre UK case cohort study. Journal of Radiotherapy in Practice page 1 of 5. doi: 10.1017/S1460396920001077.
Flamigel® RT: Clinically proven pain relief
22/04/2026
According to an independent study*, radiodermatitis affects 94% of breast cancer patients during radiotherapy. Make a difference by recommending Flamigel® RT from day 1 of treatment and help reduce the incidence of skin reactions, ensuring better care for your patients.
*Censabella S et al., Efficacy of a hydroactive colloid gel versus historical controls for the prevention of radiotherapy induced moist desquamation in breast cancer patients. Eur J Oncol Nurs. 2017;29:1-7.
Flamigel® RT: reduce radiodermatitis risk
Flamigel® RT is a hydro-active colloid gel for the symptomatic treatment of low grade radiotherapy-induced skin reactions.
06/04/2026
Clinical evidence* showed that Flamigel® RT reduced the incidence of moist desquamation by 80% versus standard care in radiotherapy patients.
A clear difference that highlights the value of recommending Flamigel® RT from day one, to help protect skin throughout treatment.
*Censabella S et al., Efficacy of a hydroactive colloid gel versus historical controls for the prevention of radiotherapy induced moist desquamation in breast cancer patients. Eur J Oncol Nurs. 2017;29:1-7.
Flamigel® RT. 80% less moist desquamation
Flamigel® RT is a hydro-active colloid gel for the symptomatic treatment of low grade radiotherapy-induced skin reactions.
